MAIA Biotechnology (MAIA) Stock Analysis
AMEXHealthcareBiotechnology
What MAIA Biotechnology does
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
Key metrics
ETFs linked to MAIA
Broad-market and Healthcare sector ETFs an investor holding MAIA Biotechnology is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how MAIA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze MAIA in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for MAIA Biotechnology?
- MAIA Biotechnology trades under the ticker MAIA on AMEX.
- Which exchange is MAIA listed on?
- MAIA is listed on AMEX.
- What sector does MAIA Biotechnology operate in?
- MAIA Biotechnology is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze MAIA in a portfolio?
- PortView shows MAIA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.